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Abstract: 
Objective: To assess the impact of HIV and antiretroviral (ARV) exposure without infection on lung 
growth and function over the first 2 years of life. 
Design: Prospective observational study of an African birth cohort, Drakenstein Child Health Study 
(DCHS). 
Method: Infants enrolled antenatally had lung function measured at 6 weeks, 1 and 2 years. HIV-infected 
women received ARV therapy (ART) as per local guidelines. The association between HIV and ARV 
exposure with lung function was assessed using mixed effects modelling. 
Results: Of 1143 infants born, 2 HIV-infected infants were excluded from analysis; 909 (80%) infants 
had lung function collected at 6 weeks (190 [21%] were HIV-exposed uninfected [HEU]); 782 (69%) at 1 
year and 741 (65%) at 2 years. At 6 weeks HEU infants had larger tidal volume (TV) compared to HIV 
unexposed infants (1.13mL, CI: 0.02 to 2.23, p= 0.045). High maternal viral load was associated with a 
17% lower expiratory flow over 2 years (0.17, CI 0.00 to 0.34, p=0.046). First-line ART initiated during 
pregnancy was associated with lower infant TV at 6 weeks compared to those who initiated ART before 
pregnancy (-2.7mL, -5.31 to -0.10, p=0.042), and low maternal CD4 cell counts associated with lower 
infant tidal over 2 years (-11.1 mL, -18.58 to 3.58, p=0.004). 
Conclusion: HIV exposure is associated with altered lung function in early life, with a vulnerable HEU 
subgroup based on maternal disease severity, immunological compromise and ART exposure. This data 
highlights the importance of ongoing surveillance of respiratory health in HEU children. 
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Background: 
Respiratory disease is the leading cause of death outside the neonatal period in children under 5 years 
worldwide[1] and despite progress towards the Sustainable Development Goals, many countries fall far 
behind the global under-5 mortality targets. This is particularly evident in Sub-Saharan Africa (SSA) 
which has the highest under-5 mortality rate globally, and where children have a 15-fold higher likelihood 
of dying before 5 years compared to high-income countries[2]. In South Africa, despite progress reducing 
other causes of death including diarrhoea, little change has been made in the proportion of deaths 
attributable to pneumonia.[3] Understanding those factors which contribute towards paediatric respiratory 
disease in SSA is therefore critical to improving public health outcomes. 
 
SSA is at the epicentre of the HIV/AIDS epidemic. The substantial reduction in perinatal transmission of 
HIV following the introduction of antiretroviral drugs (ARVs) is arguably the most significant success 
story of the epidemic, however, the number of HIV-infected women giving birth remains high, and has 
been reported as 1.4 million mothers each year for the past decade[4, 5]. The decreasing rate of paediatric 
infections means that there is a growing population of uninfected children born following HIV and ARV 
exposure, estimated around 15 million in 2017[6]. HIV-exposed uninfected (HEU) children are recognised 
as having a greater risk of mortality and morbidity compared to unexposed children early in life[7, 8]. In 
HEU children, respiratory disease is the primary cause of morbidity, with high rates of infectious 
disease[9]. Studies from South Africa have shown HEU infants have an increased risk of both bacterial 
infections including invasive pneumococcal disease [10] and viral infections such as RSV[11]. HIV 
exposure has also been found to be a key risk factor for pneumonia in infants[12, 13].  
 
In addition to global risk factors for respiratory disease in children such as poverty, maternal physical and 
psychological health, exposure to tobacco smoke and air pollution; HEU children experience additional 
risks through lower breast-feeding rates, living in HIV-affected households with higher rates of infectious 
diseases, exposure to altered immune environments in utero as well as to ARVs.[14] Limited data is 
available on the impact of ARVs, however, associations have been made with adverse birth outcomes 
including prematurity and low birth weight, and furthermore ARVs have been hypothesised to affect lung 
growth and function through dysregulation of metabolic pathways.[15] However, improved maternal health 
through antiretroviral therapy (ART) initiation before pregnancy has been shown to reduce infectious 
morbidity and hospitalisation in high-income countries[16]. 
 Few studies have assessed lung function in SSA infants and few have focussed on HEU children globally. 
Novel early data from the Drakenstein Child Health Study (DCHS), a population-based birth cohort study 
in South Africa, showed differences in tidal volume aged 6 weeks between HEU and HIV-unexposed 
(HU) children[17]. HEU infants had higher tidal volumes on average compared to HU children, which may 
reflect an effect on breathing control. It is possible that the latter could be mediated through either 
exposure to HIV, or ARVs taken by mothers and infants.  An understanding of the long term implications 
of HIV and ARV exposure on uninfected child respiratory health in an SSA context is critically 
important. 
 
In this analysis of the DCHS cohort we aimed to assess the impact of HIV and ARV exposure on lung 
growth and function over the first 2 years of life. 
 
Methods: 
 
Study design and participants 
This is a study of HIV-exposed uninfected and HIV-unexposed infants enrolled in the DCHS and who 
were followed from birth through to 2 years, with lung function measured at 6 weeks, 1 year and 2 years. 
The DCHS is a birth cohort study situated in a peri-urban, low socio-economic area outside Cape Town in 
South Africa[18]. Mothers were enrolled antenatally between March 2012 and March 2015 and followed 
through pregnancy at one of two primary care clinics with mother-child pairs followed from birth. Infants 
attended scheduled study visits at six, ten, fourteen weeks and six, nine and twelve months of age and 6 
monthly thereafter. In addition to these regular health assessments and monitoring, a strong surveillance 
system was established for the detection of lower respiratory tract illness (LRTI).  Socioeconomic status 
was assessed as a composite variable, placing participants into relative quartiles. This score is derived 
from employment status and standardized scores of: educational attainment, household income, assets and 
market access.[19] The study was approved by the Faculty of Health Sciences, Human Research Ethics 
Committee, University of Cape Town (401/2009; 423/2012) and by the Western Cape Provincial Health 
Research Committee. Parents gave informed, written consent in their first language for their infants to 
participate. 
HIV diagnosis and prevention of mother-to-child transmission (PMTCT) 
Maternal HIV infection was assessed at enrolment through self-report and routine PMTCT HIV testing. 
All HIV-infected mothers received antiretroviral drugs (ARV) according to the Western Cape Department 
of Health Guidelines for PMTCT at the time. In 2012 the guidelines advised zidovudine in all pregnant 
women and ART to be initiated as per maternal clinical/immunological status. From early-2013 onwards 
the current guidelines were introduced which are triple antitretroviral therapy (ART) irrespective of 
clinical status, made up of one non-nucleoside reverse transcriptase inhibitor plus two nucleoside reverse 
transcriptase inhibitors (typically efavirenz plus tenofovir and emtricitabine/lamivudine)[20]. HIV data 
were obtained from folder reviews of mothers and children and accessing electronic laboratory data from 
the National Health Laboratory Service (NHLS) as well as self-report interviews antenatally and 
postnatally. In the case of multiple measures, the lowest recorded CD4 count (collected 1 year before to 3 
months after birth to maximise numbers) and highest viral load during pregnancy were used. HIV-
exposed children were tested for HIV at 6 weeks (by PCR), 9 months (by PCR, ELISA or rapid antibody 
testing), and 18 months (by rapid antibody testing), as per provincial PMTCT guidelines.  
 
Lung function measures 
Lung function testing was undertaken first at six (5-11) weeks of age corrected for prematurity (<37 
weeks) and then at one year (11-13 months) and two years (23-25 months). All testing was done in 
unsedated, behaviourally assessed quiet sleep as previously described.[21, 22] Lung function tests included 
measures of tidal breathing (tidal volume, respiratory rate, expiratory flow ratios) and sulphur-
hexafluoride (SF6) multiple breath washout (MBW), which measures functional residual capacity (FRC) 
and the lung clearance index. The tidal lung volumes are a measure of lung growth. Low expiratory flow 
ratio (time to peak tidal expiratory flow over total expiratory time [tPTEF/tE]) reported here is associated 
with airway obstruction, though is also affected by lung size and breathing control.[23] The lung clearance 
index is an early measure of small airways disease and impaired ventilation, it increases in disease 
states.[24]  Measurements were collected using the Exhalyser D with ultrasonic flow meter (Ecomedics 
AG, Duernton, Switzerland) with 4% SF6 for the MBW.[21]  
 
 
 
Statistical analysis 
Analyses were conducted with STATA version 14.0 (College Station, Texas, USA). Descriptive data was 
presented as means, standard deviations (SD) and frequencies (proportions), as appropriate. Mann-
Whitney rank sum tests was used to test for significant differences between categorical and continuous 
variables. Pearson Chi-square test or Fisher Exact tests were used to determine if significant differences 
existed between categorical variables.  
 
Lung function outcomes were modelled using linear regression to assess the impact of HIV exposure, 
maternal HIV disease severity and ARV exposure on the lung function attained at each time point. 
Maternal HIV viral load was used as a categorical variable: undetectable (<40 copies/mL), detectable 
(>=40-1000 copies/mL) and virally unsuppressed (>1000 copies/mL). Maternal CD4 count was 
categorised as: > 500 cells/ mm3,  350-500 cells/ mm3 and <=350 cells/mm3. BMI for age z scores were 
calculated using the WHO Child Growth Standards “Igrowup” STATA package.   
Base models were first constructed using Directed Acyclic Graphs (DAGs) for confounder selection. 
DAGs minimal adjustment set of variables (socio-economic status (SES), race, sex, BMI for age, 
maternal smoking) were used to assess the impact of exposures on lung function outcomes at each time 
point (6 weeks, 12 months and 24 months). In addition, mixed effects models were used to assess the 
impact of HIV and ARV exposure on lung growth over 2 years. In this model LRTI episodes during 2 
years was included given the documented impact of LRTI on lung function outcomes in this cohort.[25]  
For ARV exposure, analyses were performed comparing all those children exposed to maternal triple 
ART, compared to AZT-only. However, for timing of ART initiation we limited to the first-line regimen 
that the majority of women were receiving in the study (tenofovir [TDF]/emtricitabine [FTC]/efavirenz 
[EFV]) which is currently WHO recommended first-line in our setting (dolutegravir is not yet widely 
available), and by limiting to one regimen we were able to better examine the effects of timing without 
the confounding effects of different ARV drugs. Estimated coefficients, 95% confidence intervals and p-
values were recorded for each early life exposure of interest. 
 
In addition, diagnostic checks were conducted.  These included checking for normality in the residuals 
using histograms, standardised probability (P-P) plot, Quantile-Quantile (Q-Q) plots, as well the Shapiro-
Wilk W test for normality. Further, homoscedasticity was checked using scatter plots and the presence of 
multicollinearity was explored using the variance inflation factor (VIF). Three of the lung function 
measures (functional residual capacity , ratio of time to peak tidal expiratory flow over total time of 
expiration, and respiratory rate) were found to be non-normal, and thus log-transformations were 
performed on these outcomes.  
 
Results: 
 
Due to the successful PMTCT programme only 2 of the 1143 infants born in the DCHS were HIV-
infected, and these children were excluded from this analysis. Of the 1141 infants, 909 (80%) infants had 
lung function measured at 6 weeks; 190 (21%) were HEU; 473 (52%) male, 477 (53%) black African 
ancestry, 294 (33%) mothers smoked during pregnancy, 653 (72%) had household tobacco smoke 
exposure, table 1. At one year 782 (69%) infants and at 2 years 741 (65%) infants had lung function 
measures collected, testing success rates shown in figure 1. HIV exposure prevalence was similar between 
those who were tested at 12 and 24 months and those who were not, table S1 and S2 
http://links.lww.com/QAD/B588. The majority of HEU infants were black African (93% vs. 42% HU, 
p<0.001), HEU infants had less household smoke exposure (68% vs. 81%, p<0.001) and fewer HEU 
infants mothers smoked during pregnancy (26% vs. 35%, p=0.03); HEU infants had shorter breastfeeding 
duration, although both groups were low (1.55 [2.15] vs. 2.22 [1.88] months; p<0.001) and lower SES 
(lowest SES 31% vs. 22%; p=0.006) at 6 weeks compared to HU; other demographics were similar, table 
1. More HEU infants had a LRTI during the first 2 years of life than HU (49% vs. 37.6%, p=0.04). 
 
The majority of mothers, 158 (85%), were on triple therapy ART at the time of delivery (147 [93%]on 
first-line therapy, of which 123[ 78%} were on 3TC/EFV/TDF, WHO recommended 1st line therapy). Of 
these 75/123 (61%) were started on therapy during pregnancy, table 1. Twenty nine (18%) mothers were 
on AZT only as per the PMTCT guidelines at the time. Seventy-two (41%) of mothers had CD4 counts 
>=500 cells/mm3, 65 (37%) had low CD4 cell counts (<350 cells/mm3) and the rest between 350-500 
cells/mm3.  Of those with viral load taken during pregnancy, the majority of mothers (69, 61%) had a 
suppressed HIV viral load; 18 (16%) mothers had high viral loads of >1000 copies/mL.  
 
 
Effects of HIV exposure on lung function 
At 6 weeks of age HEU had a larger tidal volume compared to HU, mean (SD) 35.9mL (6.3) vs. 34.6 mL 
(6.4); present after adjusting for confounding factors, (1.13mL, CI: 0.02 to 2.23, p= 0.045), table 2 and 
S1. This effect did not sustain over 2 years, with similar tidal volumes between groups over two years, 
table 3.  
The lung clearance index (LCI) was higher in HEU compared to HU at both 12 (6.8 vs. 6.7, p=0.032) and 
24 months (6.8 vs. 6.7, p=0.003); this was an average 0.12 (CI 0.02 to 0.23, p=0.020) turnovers higher at 
2 years compared to HU, table S1 http://links.lww.com/QAD/B588. However, this trend was not 
statistically significant over 2 years in the multivariate model, table 3. HEU had a higher average 
respiratory rate compared to HU at 12 months (30.6 vs. 29.5, p=0.007) which was not seen at 24 months, 
table S1  http://links.lww.com/QAD/B588. The FRC and tPTEF/tE were similar between groups. 
 
Effects of maternal HIV disease and ARV exposure on lung function 
Impact of maternal CD4 count: 
Compared to HU, infants whose mothers had a CD4 count >500 cells/mm3 had higher tidal volumes at 6 
weeks, average 2.0 mL (CI 0.46 to 3.56, p=0.01), table 2 compared to those <500 cells/mm3. Over 2 
years, a low maternal CD4 count (<350 cells/mm3) was associated with a higher LCI (0.1, CI 0.02 to 0.21, 
p=0.02), however this was not significant when adjusted for potential confounders. Maternal CD4 during 
pregnancy had no effect on FRC, respiratory rate nor tPTEF/tE measures at 2 years. However in those 
children exposed to first-line triple ART, low maternal CD4 counts were associated with lower infant 
tidal volume over 2 years, average 11.1 mL lower (CI-18.58 to 3.58, p=0.004), table 4.  
 
Impact of maternal HIV viral load: 
Having a mother with an unsuppressed HIV viral load (>1000 copies/mL), was associated with a 17% 
lower expiratory flow ratio time to peak tidal expiratory flow over total expiratory time (tPTEF/tE) at 6 
weeks, CI-0.34 to -0.01, p=0.044, table 2. Over 2 years, a high maternal viral load (>1000 copies/mL) 
was associated with an increased LCI (0.17, CI 0.00 to 0.34, p=0.046) and a 13% lower tPTEF/tE, (CI-0.26 
to -0.01, p=0.037), table 3. Maternal viral load was not associated with respiratory rate, tidal volume nor 
FRC over 2 years. 
The impact of ARV exposure on lung function:  
Compared to HU infants, infants exposed to AZT had a higher tPTEF/tE (0.17, 0.04-0.30, p=0.009) and 
higher tidal volumes (2.37, CI 0.08 to 4.67, 0.043) at 6 weeks, table 2. Amongst the HEU, those exposed 
to triple ART, had lower tPTEF/tE at 6 weeks compared to infants exposed to AZT, (-0.30, -0.45 to 0.14, 
p<0.001), an effect that was not sustained over 2 years, table S2 http://links.lww.com/QAD/B588. In 
analyses limited to infants exposed to current WHO first-line triple ART (table 4), ART initiated during 
pregnancy was associated with lower infant tidal volumes at 6 weeks compared to those who had ART 
initiated prior to pregnancy,  average 2.7mL lower (-5.31 to -0.10, p=0.042).  
 
Discussion 
This paper provides novel data on the impact of HIV and ARV exposure  on the developing lung function 
trajectory over the first two years of life in an African birth cohort from a high HIV prevalence area. We 
show that HIV exposure is associated with altered lung function soon after birth and at 2 years of age. 
Overall these effects were mild. The study identified both uncontrolled maternal HIV disease (as 
measured by high HIV viral load), immunological compromise and ART initiation during pregnancy as 
factors associated with poorer lung function outcomes. 
 
The impact of HIV exposure on tidal volume at 6 weeks has been previously published.[17] The 6 week 
lung function reflects in part the impact of the antenatal environment when the fetus is more directly 
exposed to their mother’s immunity, ARVs and potentially the HIV virus. The average increase in tidal 
volume was small, but statistically significant even after correcting for somatic growth and other 
predictors. We had previously hypothesised that the increased tidal volume could be related to breathing 
control affected by ARVs, although respiratory rate and expiratory flow ratios were not different. AZT 
exposure in children can cause anaemia and lactic acidosis, both may affect breathing pattern.[26] 
However, we did not have data to assess this in our cohort; in addition the numbers of children exposed to 
AZT was small and should be interpreted with caution. This association warrants further investigation, 
although with current PMTCT recommendations HEU infants are unlikely to be exposed to AZT 
antenatally in the future, however, they continue to have postnatal exposure prophylaxis.[20] 
 
The early effects of HIV on tidal volume were not sustained over 2 years and, in fact, HIV exposure had 
no independent effect on any lung function outcomes over 2 years.  This is interesting in the context of 
current literature emerging around HEU children. A recent study found an association between HIV 
exposure without infection and early child growth trajectories.[27] In addition, another study from the 
Drakenstein Child Health Study found HEU children were at increased risk of hospitalised LRTI in the 
first 6 months of life.[12] It is likely all of these variables are interlinked, and we corrected for LRTI and 
child growth in the multivariate models. Although we did not find an effect of maternal HIV alone, we 
found associations with maternal viral load and CD4.  
 
In this study HEU infants whose mothers had high HIV viral loads, had higher LCI at 2 years, evidence of 
the association between maternal disease status and infant respiratory health. A high maternal viral load 
was also associated with reduced expiratory flow ratios (tPTEF/tE) at 6 weeks, which persisted over 2 years. 
This effect was present even after correcting for early life LRTI and other predictors. This data suggest 
that a sub-group of HEU children whose mothers have more advanced HIV disease may be most 
vulnerable to lung function impairment and require closer follow-up. 
 
Assessing the impact of ARVs on lung function was affected by our cohort being a heterogeneous group, 
which is similar to other SSA settings. The PMTCT guidelines, as well as adult ART initiation guidelines, 
changed during the early stages of the cohort follow-up and hence not all infants were exposed to the 
same maternal ART regimens, however, the majority of mothers were on WHO recommended first line 
triple therapy reflecting current PMTCT guidelines. When analysing this group separately, initiation of 
ART during pregnancy and low CD4 cell counts were associated with lower tidal volume at 6 weeks and 
over 2 years respectively. This suggests that earlier ART initiation in mothers is beneficial to infant lung 
growth, highlighting the importance of maternal health in influencing child respiratory outcomes. This is 
similar to a recent study from Belgium which showed that maternal ART initiation before pregnancy 
reduced the infection-related hospitalization risk and had associations with the HEU infant immunological 
status[16]. 
This study has many strengths. It is a large birth cohort within a high HIV prevalence area, followed 
longitudinally through to 2 years with good retention of 86%. Comprehensive lung function measures 
were collected at birth and annually, allowing the assessment of exposure impact over time. There was 
robust collection of other risk factor information such as tobacco smoke exposure and early life LRTI, 
allowing us to account for these factors in analysis. The fact that ART treatment protocols were not 
consistent during the early study, meant that there was heterogeneity of ART exposure and maternal 
disease markers which is reflective of many other SSA countries and hence speaks to the generalisability 
of this data. A limitation of the study is that we had a large amount of missing viral load (VL) data, which 
reduced our statistical power to assess the impact of HIV VL on outcomes and further work is needed to 
replicate our findings. In addition potential confounders excluded may have an impact on our analysis, 
but we feel that the covariates included reduce residual confounding. 
 
Conclusion 
This is the first study to comprehensively assess the impact of HIV exposure and antiretroviral therapy on 
infant lung function and growth during early life. It shows that HIV exposure has mild impacts on lung 
function and growth during early life and that maternal disease severity as measured by low CD4 count 
and high HIV viral load increases risk of lung function impairment. These findings need to be validated in 
other cohort studies, where HIV and respiratory disease risk factor prevalences differ. The impact of 
ARVs and timing of ART initiation support the current WHO guidelines, however, the longer term 
implications of these findings require further investigation, which we are undertaking. This study 
highlights the importance of monitoring and follow-up of HEU infants, particularly those whose mothers 
have poor disease control. 
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 Figures 
 
Figure1: Flow chart of cohort (include number included at each time point with successful testing) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*TBVL: tidal breathing flow volume analyses (tidal volume, respiratory rate and flow ratios) **MBW: 
multiple breath washout (functional residual capacity and lung clearance index) 
  
Infants tested at 6 weeks: TBVL* and MBW** 
N=909 
Tests successful:  
TBVL n = 857 (94%), MBW n=809 (89%) 
 
Tested at 1 year: TBVL and MBW 
N=782 
Tests successful: 
TBFVL n=729 (93%), MBW n=688 (88%) 
Tested at 2 year: TBFVL and MBW 
N=741 
Tests successful:  
TBVL N = 646 (87%), MBW N= 621 (84%) 
 
1143 infants born on Drakenstein 
Child Health Study 
Excluded: 
HIV infected n=2 
1141 infants eligible for inclusion 
Tables 
Table 1 Demographics and exposures of cohort at 6 weeks 
 Total  
(n=909) 
HIV exposed  
(n=190) 
HIV 
unexposed 
(n=719) 
P-value1
Socio-demographic characteristics  
Male sex 473 (52.0%) 97 (51.1%) 376 (52.3%) 0.093 
Ethnicity     
  African-ancestry 477 (52.5%) 177 (93.2%) 300 (41.7%) <0.001 
  Mixed-ancestry 432 (47.5%) 13 (6.8%) 419 (58.3%) - 
SES Quartiles     
  Lowest SES 218 (24.0%) 59 (31.1%) 159 (22.1%) 0.006 
  Low-Mod SES 237 (26.1%) 56 (29.5%) 181 (25.2%) - 
  Mod-High SES 234 (25.7%) 43 (22.6%) 191 (26.6%) - 
  High SES 220 (24.2%) 32 (16.8%) 188 (26.2%) - 
Preterm (< 37 weeks) 140 (15.4%) 30 (15.8%) 110 (15.35) 0.879 
BMI Z-score  0.15 (1.17) 0.24 (1.21) 0.12 (1.16) 0.096 
Maternal cotinine 
results* 
    
  Non-smoker 202 (22.8%) 42 (22.5%) 160 (22.9%) 0.026 
  Passive smoker 391 (44.1%) 97 (51.9%) 294 (42.0%) - 
  Active smoker 294 (33.1%) 48 (25.6%) 246 (35.1%) - 
Infant cotinine results*     
  No smoke exposure 183 (21.9%) 57 (32.2%) 126 (19.1%) <0.001 
 Moderate smoke 
exposure 
585 (70.0%) 113 (63.8%) 472 (71.6%) - 
  High smoke exposure 68 (8.1%) 7 (4.0%) 61 (9.3%) - 
Duration of exclusive 
breastfeeding (months)  
2.08 (1.96) 1.55 (2.15) 2.22 (1.88) <0.001 
LRTI during 2 years 363 (39.9%) 93 (49.0%) 270 (37.6%) 0.004 
Maternal TB  41 (4.5%) 24 (12.6%) 17 (2.4%) <0.001 
Maternal HIV     
variables  
Maternal CD4 cell 
count* 
    
  >=500 cells/ mm3 72 (8.0%) 72 (40.9%)   
  350-500 cells/ mm3 39 (4.4%) 39 (22.2%)   
  <350 cells/ mm3 65 (7.3%) 65 (36.9%)   
Maternal Viral load (VL) in pregnancy*
  Lower than detectable   
limit (<40 copies/mL) 
69 (8.3%) 69 (61.1%)   
  VL detectable (>=40-
1000 copies/mL) 
26 (3.1%) 26 (23.0)   
  Virally unsuppressed 
(>1000 copies/mL) 
18 (2.2%) 18 (15.9%)   
ART regimen during pregnancy* 
 PMTCT prophylaxis 
(AZT) 
29 (3.3%) 29 (15.5%)   
 ART** 158  (17.4% ) 158  (84.5%)   
1st / 2nd/ 3rd line ART 
1st line ART 147 (16.2%) 147 (93.0%)    
2nd/ 3rd ART 11 (0.1%) 11 (7.0%)   
ART initiation 
timepoint limited to 
current WHO first line 
ART*** 
    
  Before pregnancy 48 (5.3%) 48/123 (39.0%)   
  During pregnancy 75 (8.5%) 75/123 (61.0%)   
Infant prophylaxis     
 NVP alone 165 (18.2%) 165 (87.8%)   
 NVP + AZT  23 (2.5%) 23 (12.2%)   
 
1Unpaired t-test used for continuous variables (means and SD presented); Chi-squared for categorical 
variables (n and % proportions presented).  
*Missing data: Maternal cotinine results had 22 missing values – 3 HIV exposed, and 19 HIV unexposed; 
Infant cotinine results had 73 missing values – 13 HIV exposed and 60 HIV unexposed; Maternal HIV 
diagnosis time point had 2 missing values; Maternal CD4 count had 14 missing values; Maternal viral 
load in pregnancy had 77 missing values; ART regimen had 25 missing values; 1st line/ 2nd/3rd line 
therapy had 3 missing values; Infant prophylaxis had 2 missing values.  
 
Abbreviations: BMI= Body mass index; LRTI= Lower respiratory tract infection; TB= Tuberculosis; 
ART= Antiretroviral treatment AZT = Zidovudine; KAL= Kaletra (lopinavir/ritonavir); D4T= Stavudine; 
NVP= Nevirapine; EFV=efavirenz; TDF=tenofovir 
 
**ART = 3TC/EFV/TDF (n=123); 3TC/AZT/EFV (n=3); 3TC/AZT/KAL (n=5);  3TC/AZT/NVP (n=6); 
3TC/AZT/RIT/ATV (n=1); 3TC/KAL/TDF (n=5); 3TC/NVP/TDF (n=11); 3TC/d4t/EFV (n=2); 
3TC/d4t/NVP (n=2)  
***Restricted to WHO recommended 1st line ART the majority of mothers received either separately or as 
fixed dose combination: 3TC/EFV/TDF 
 
  
Table 2 Impact of HIV, maternal disease and ARV on lung function at 6 weeks 
 Log (FRC) LCI Log (tptef/te) Tidal Volume Log 
(Respiratory 
rate) 
 Unadj
usted  
coeffici
ent  
(95% 
CI), p 
Adjus
ted 
coeffi
cient  
(95% 
CI)*, 
p 
Unadj
usted 
coeffici
ent  
(95% 
CI), p 
Adjus
ted 
coeffi
cient 
 (95% 
CI)*, 
p 
Unadj
usted 
coeffici
ent 
 (95% 
CI), p 
Adjus
ted 
coeffi
cient  
(95% 
CI)*, 
p 
Unadj
usted 
coeffici
ent 
 (95% 
CI), p 
Adjus
ted 
coeffi
cient 
 (95% 
CI)*, 
p 
Unadj
usted 
coeffici
ent 
 (95% 
CI), p 
Adjus
ted 
coeffi
cient 
 (95% 
CI)*, 
p 
Materna
l HIV: 
    No        
Refere
nce 
Refere
nce 
(N=78
8) 
Refere
nce 
Refere
nce 
(N=78
8) 
Refere
nce 
Refere
nce 
(N=83
6) 
Refere
nce  
Refere
nce 
(N=83
6) 
Refere
nce 
Refere
nce 
(N=83
6) 
    Yes      0.02 (-
0.02; 
0.05), 
0.330 
0.02 (-
0.02; 
0.05), 
0.422 
-0.01 (-
0.08; 
0.07), 
0.818 
-0.03 
(-0.11; 
0.06), 
0.495 
0.04 (-
0.01; 
0.10), 
0.144 
-0.01 
(-0.07; 
0.05), 
0.757 
1.29 
(0.23; 
2.35), 
0.017 
1.13 
(0.02; 
2.23), 
0.045 
0.02 (-
0.01; 
0.06), 
0218 
-0.01 
(-0.05; 
0.04), 
0.802 
CD4 
(cells/m
m3):  
     > 500 
Refere
nce 
Refere
nce 
(N=15
1) 
Refere
nce 
Refere
nce 
(N=15
1) 
Refere
nce 
Refere
nce 
(N=15
9) 
Refere
nce  
Refere
nce 
(N=15
9) 
Refere
nce 
Refere
nce 
(N=15
9) 
    350-
500 
0.00 (-
0.09; 
0.09), 
0.991 
-0.01 
(-0.09; 
0.08), 
0.900 
-0.09 (-
0.26; 
0.08), 
0.303 
-0.09 
(-0.26; 
0.09), 
0.343 
0.01 (-
0.11; 
0.13), 
0.881 
0.10 (-
0.03; 
0.24), 
0.269 
-1.91 (-
4.48; 
0.67), 
0.145 
-1.21 
(-3.72; 
1.30), 
0.341 
0.05 (-
0.05; 
0.15), 
0.298 
0.03 (-
0.07; 
0.13), 
0.560 
     
<=350 
-0.02 (-
0.10; 
0.05), 
0.535 
-0.02 
(-0.10; 
0.06), 
0.605 
0.00 (-
0.15; 
0.15), 
0.964 
0.03 (-
0.13; 
0.18), 
0.710 
0.11 (-
0.03; 
0.24), 
0.120 
-0.01 
(-0.13; 
0.11), 
0.891 
-1.78 (-
4.04; 
0.48), 
0.122 
-1.58 
(-3.78; 
0.62), 
0.158 
0.04 (-
0.04; 
0.13), 
0.332 
0.04 (-
0.05; 
0.13), 
0.401 
CD4 
with 
Refere
nce 
Refere
nce 
Refere
nce 
Refere
nce 
Refere
nce 
Refere
nce 
Refere
nce  
Refere
nce 
Refere
nce 
Refere
nce 
unexpos
ed 
group:     
      
HUU 
(N=77
6) 
(N=77
6) 
(N=82
3) 
(N=82
3) 
(N=82
3) 
      > 
500  
0.03 (-
0.03; 
0.08), 
0.349 
0.02 (-
0.03; 
0.08), 
0.403 
0.01 (-
0.11; 
0.12), 
0.925 
-0.02 
(-0.14; 
0.10), 
0.724 
0.02 (-
0.07; 
0.10),  
0.71 
-0.03 
(-0.12; 
0.06), 
0.526 
2.44 
(0.84; 
4.03), 
0.003 
2.01 
(0.46; 
3.56), 
0.011 
-0.01 (-
0.07; 
0.05), 
0.655 
-0.03 
(-0.09; 
0.03), 
0.268 
     350-
500 
      
0.03 (-
0.04; 
0.09), 
0.470 
0.03 (-
0.04; 
0.10), 
0.372 
-0.08 (-
0.23; 
0.07), 
0.274 
-0.12 
(-0.27; 
0.04), 
0.156 
0.12 
(0.01; 
0.23), 
0.034 
0.09 (-
0.03; 
0.21), 
0.131 
0.53 (-
1.59; 
2.65), 
0.623 
0.90 (-
1.17; 
2.96), 
0.396 
0.04 (-
0.04; 
0.12), 
0.324 
-0.01 
(-0.09; 
0.07), 
0.853 
     
<=350  
    
0.00 (-
0.05; 
0.06), 
0.980 
0.00 (-
0.06; 
0.06), 
0.928 
0.01 (-
0.11; 
0.13), 
0.887 
-0.00 
(-0.13; 
0.13), 
0.988 
0.03 (-
0.07; 
0.12), 
0.594 
-0.04 
(-0.13; 
0.06), 
0.448 
0.66 (-
1.07; 
2.39), 
0.456 
0.45 (-
1.24; 
2.14), 
0.602 
0.03 (-
0.03; 
0.09), 
0.360 
-0.00 
(-0.07; 
0.06), 
0.960 
Viral 
Load: 
     HUU 
Refere
nce 
Refere
nce 
(N=72
0) 
Refere
nce 
Refere
nce 
(N=72
0) 
Refere
nce 
Refere
nce 
(N=76
6) 
Refere
nce  
Refere
nce 
(N=76
6) 
Refere
nce 
Refere
nce 
(N=76
6) 
     
Undetec
table#    
0.01 (-
0.05; 
0.06), 
0.791 
0.00 (-
0.05; 
0.06), 
0.938 
-0.04 (-
0.16; 
0.08), 
0.555 
-0.06 
(-0.19; 
0.06), 
0.316 
0.03 (-
0.06; 
0.11), 
0.567 
-0.03 
(-0.13; 
0.06), 
0.469 
1.44 (-
0.20; 
3.08), 
0.085 
0.97 (-
0.61; 
2.56), 
0.227 
0.05 (-
0.01; 
0.11), 
0.095 
0.02 (-
0.04; 
0.09), 
0.440 
     
Detectab
le#  
0.02 (-
0.06; 
0.11), 
0.576 
0.04 (-
0.05; 
0.12), 
0.494 
0.12 (-
0.08; 
0.30), 
0.234 
0.08 (-
0.12; 
0.28), 
0.438 
-0.09 (-
0.23; 
0.06), 
0.231 
-0.14 
(-0.29; 
0.01), 
0.061 
1.47 (-
1.25; 
4.18), 
0.290 
2.27 (-
0.32; 
4.86), 
0.086 
0.04 (-
0.06; 
0.13), 
0.480 
-0.02 
(-0.12; 
0.08), 
0.644 
    
Virally   
    
unsuppr
-0.02 (-
0.11; 
0.09), 
0.773 
-0.01 
(-0.11; 
0.09), 
0.911 
0.02 (-
0.20; 
0.25), 
0.830 
0.00 (-
0.22; 
0.23), 
0.990 
-0.13 (-
0.29; 
0.04), 
0.124 
-0.17 
(-
0.34; -
0.01), 
-0.04 (-
3.12; 
3.03), 
0.978 
0.11 (-
2.74; 
2.97), 
0.938 
-0.00 (-
0.11; 
0.11), 
0.987 
-0.02 
(-0.13; 
0.09), 
0.666 
essed#   0.044 
Treatme
nt:  
    AZT 
Refere
nce 
Refere
nce 
(N=16
0) 
Refere
nce 
Refere
nce 
(N=16
0) 
Refere
nce 
Refere
nce 
(N=16
9) 
Refere
nce  
Refere
nce 
(N=16
9) 
Refere
nce 
Refere
nce 
(N=16
9) 
   Triple 
therapy     
-0.06 (-
0.14; 
0.03), 
0.175 
-0.06 
(-0.15; 
0.02), 
0.145 
0.14 (-
0.04; 
0.31), 
0.126 
0.13 (-
0.05; 
0.31), 
0.157 
-0.21 (-
0.34; -
0.08), 
0.002 
-0.25 
(-
0.38; -
0.11), 
<0.00
1 
-1.79 (-
4.39; 
0.80), 
0.175 
-1.43 
(-3.99; 
1.14), 
0.273 
0.07 (-
0.03; 
0.17), 
0.152 
0.07 (-
0.03; 
0.17), 
0.187 
Treatme
nt with 
unexpos
ed 
group:  
     HUU 
Refere
nce 
Refere
nce 
(N=78
8) 
Refere
nce 
Refere
nce 
(N=78
8) 
Refere
nce 
Refere
nce 
(N=83
6) 
Refere
nce  
Refere
nce 
(N=83
6) 
Refere
nce 
Refere
nce 
(N=83
6) 
     AZT 0.06 (-
0.02; 
0.14), 
0.113 
0.06 (-
0.02; 
0.13), 
0.166 
-0.12 (-
0.30; 
0.05), 
0.158 
-0.14 
(-0.31; 
0.04), 
0.127 
0.21 
(0.08; 
0.34), 
0.001 
0.17 
(0.04; 
0.30), 
0.009 
2.73 
(0.28; 
5.18), 
0.029 
2.29 
(0.00; 
4.59), 
0.050 
-0.03 (-
0.12; 
0.06), 
0.481 
-0.05 
(-0.14; 
0.04), 
0.312 
    Triple 
therapy     
0.00 (-
0.03; 
0.04), 
0.875 
0.00 (-
0.04; 
0.04), 
0.948 
0.01 (-
0.07; 
0.09), 
0.800 
-0.01 
(-0.10; 
0.80), 
0.799 
0.00 (-
0.06; 
0.06), 
0.879 
-0.05 
(-0.12; 
0.02), 
0.129 
0.94 (-
0.20; 
2.08), 
0.107 
0.73 (-
0.44; 
1.91), 
0.222 
0.04 (-
0.00; 
0.80), 
0.061 
0.01 (-
0.04; 
0.05), 
0.702 
*Multivariable models adjusted for socio-economic status, race, sex, BMI for age, maternal smoke (urine 
cotinine results) 
#Undetectable: <40 copies/mL; detectable: 40-1000 copies/mL; virally unsuppressed: >1000 copies/mL 
  
Table 3 Impact of HIV, maternal disease and ARV on lung function over 24 months 
 Log (FRC) LCI Log (tptef/te) Tidal Volume Log 
(Respiratory 
rate) 
 Unadj
usted  
coeffici
ent  
(95% 
CI), p 
Adjus
ted 
coeffi
cient  
(95% 
CI)*, 
p 
Unadj
usted 
coeffici
ent  
(95% 
CI), p 
Adjus
ted 
coeffi
cient 
 (95% 
CI)*, 
p 
Unadj
usted 
coeffici
ent 
 (95% 
CI), p 
Adjus
ted 
coeffi
cient  
(95% 
CI)*, 
p 
Unadj
usted 
coeffici
ent 
 (95% 
CI), p 
Adjus
ted 
coeffi
cient 
 (95% 
CI)*, 
p 
Unadj
usted 
coeffici
ent 
 (95% 
CI), p 
Adjus
ted 
coeffi
cient 
 (95% 
CI)*, 
p 
Materna
l HIV: 
    No        
Refere
nce 
Refere
nce 
(N=97
7) 
Refere
nce 
Refere
nce 
(N=97
7) 
Refere
nce 
Refere
nce 
(N=98
6) 
Refere
nce  
Refere
nce 
(N=98
6) 
Refere
nce 
Refere
nce 
(N=98
6) 
    Yes      0.01 (-
0.05; 
0.07), 
0.792 
0.02 (-
0.05; 
0.08), 
0.628 
0.06 
(0.01; 
0.12), 
0.030 
0.03 (-
0.03; 
0.10), 
0.313 
0.03 (-
0.02; 
0.07), 
0.235 
-0.03 
(-0.08; 
0.02), 
0.221 
2.39 (-
.145; 
6.24), 
0.223 
2.87 (-
1.41; 
7.15), 
0.189 
0.02 (-
0.01; 
0.05), 
0.217 
-0.02 
(-0.06; 
0.01), 
0.227 
CD4 
(cells/m
m3):  
     > 500 
Refere
nce 
Refere
nce 
(N=19
5) 
Refere
nce 
Refere
nce 
(N=19
5) 
Refere
nce 
Refere
nce 
(N=19
6) 
Refere
nce  
Refere
nce 
(N=19
6) 
Refere
nce 
Refere
nce 
(N=19
6) 
    350-
500 
-0.06 (-
0.20; 
0.09), 
0.449 
-0.01 
(-0.15; 
0.14), 
0.902 
-0.00 (-
0.15; 
0.14), 
0.953 
-0.01 
(-0.15; 
0.13), 
0.847 
0.05 (-
0.06; 
0.16), 
0.371 
0.02 (-
0.09; 
0.13), 
0.700 
-3.60 (-
13.00; 
5.80), 
0.452 
-0.79 
(-
10.20; 
8.62), 
0.869 
0.06 (-
0.02; 
0.14), 
0.171 
0.04 (-
0.04; 
0.12), 
0.325 
     
<=350 
-0.06 (-
0.18; 
0.07), 
0.373 
-0.03 
(-0.15; 
0.09), 
0.657 
0.08 (-
0.04; 
0.20), 
0.216 
0.08 (-
0.03; 
0.20), 
0.165 
-0.00 (-
0.094; 
0.09), 
0.971 
'-0.04 
(-0.13; 
0.06), 
0.422 
-4.23 (-
12.37; 
3.92), 
0.309 
-2.48 
(-
10.52; 
5.57), 
0.546 
0.05 (-
0.02; 
0.12), 
0.127 
0.04 (-
0.03; 
0.11), 
0.221 
CD4 
with 
unexpos
ed 
group:     
      
HUU 
Refere
nce 
Refere
nce 
(N=96
0) 
Refere
nce 
Refere
nce 
(N=96
0) 
Refere
nce 
Refere
nce 
(N=96
9) 
Refere
nce  
Refere
nce 
(N=96
9) 
Refere
nce 
Refere
nce 
(N=96
9) 
      > 
500  
0.03 (-
0.06; 
0.12), 
0.493 
0.02 (-
0.07; 
0.12), 
0.657 
0.04 (-
0.05; 
0.13), 
0.342 
0.02 (-
0.07; 
0.12), 
0.609 
0.02 (-
0.05; 
0.08), 
0.573 
-0.02 
(-0.09; 
0.04), 
0.479 
4.23 (-
1.55; 
10.01), 
0.151 
3.87 (-
2.18; 
9.92), 
0.210 
-0.01 (-
0.06; 
0.04), 
0.617 
-0.05 
(-0.10; 
0.01), 
0.083 
     350-
500 
      
-0.02 (-
0.15; 
0.10), 
0.698 
0.01 (-
0.11; 
0.14), 
0.835 
0.04 (-
0.08; 
0.16), 
0.487 
-0.02 
(-0.14; 
0.11), 
0.804 
0.07 (-
0.02; 
0.16), 
0.132 
0.01 (-
0.08; 
0.10), 
0.833 
0.63 (-
7.21; 
8.46), 
0.875 
2.77 (-
5.27; 
10.82)
, 
0.499 
0.04 (-
0.02; 
0.11), 
0.212 
-0.02 
(-0.09; 
0.05), 
0.636 
     
<=350  
    
-0.02 (-
0.12; 
0.07), 
0.617 
-0.01 
(-0.11; 
0.09), 
0.893 
0.11 
(0.02; 
0.21), 
0.017 
0.08 (-
0.02; 
0.18), 
0.129 
0.02 (-
0.05; 
0.09), 
0.635 
-0.05 
(-0.12; 
0.02), 
0.187 
0.01 (-
6.27; 
6.28), 
0.998 
0.59 (-
5.91; 
7.09), 
0.859 
0.04 (-
0.01; 
0.10), 
0.136 
-0.01 
(-0.06; 
0.05), 
0.839 
Viral 
Load: 
     HUU 
Refere
nce 
Refere
nce 
(N=89
4) 
Refere
nce 
Refere
nce 
(N=89
4) 
Refere
nce 
Refere
nce 
(N=90
2) 
Refere
nce  
Refere
nce 
(N=90
2) 
Refere
nce 
Refere
nce 
(N=90
2) 
     
Undetec
table#    
0.05 (-
0.04; 
0.14), 
0.252 
0.04 (-
0.06; 
0.13), 
0.463 
0.01 (-
0.08; 
0.10), 
0.847 
-0.02 
(-0.10; 
0.09), 
0.963 
0.03 (-
0.03; 
0.09), 
0.365 
-0.03 
(-0.10; 
0.04), 
0.417 
4.18 (-
1.55; 
9.92), 
0.153 
3.52 (-
2.54; 
9.58), 
0.255 
0.03 (-
0.02; 
0.08), 
0.307 
-0.01 
(-0.06; 
0.04), 
0.696 
     
Detectab
le#  
0.01 (-
0.14; 
0.16), 
0.916 
0.06 (-
0.09; 
0.21), 
0.452 
0.12 (-
0.02; 
0.27), 
0.102 
0.07 (-
0.08; 
0.22), 
0.380 
-0.05 (-
0.16; 
0.06), 
0.379 
-0.12 
(-
0.23; -
0.01), 
0.039 
5.44 (-
4.13; 
15.01), 
0.265 
8.12 (-
1.51; 
17.75)
, 
0.098 
0.02 (-
0.06; 
0.10), 
0.633 
-0.04 
(-0.13; 
0.04), 
0.308 
    
Virally   
    
unsuppr
essed#   
-0.00 (-
0.17; 
0.17), 
0.994 
0.01 (-
0.15; 
0.18), 
0.874 
0.22 
(0.06; 
0.39), 
0.009 
0.17 
(0.00; 
0.34), 
0.046 
-0.08 (-
0.20; 
0.04), 
0.208 
-0.13 
(-
0.26; -
0.01), 
0.037 
3.18 (-
7.65; 
14.01), 
0.565 
4.22 (-
6.57; 
15.01)
, 
0.444 
0.01 (-
0.09; 
0.10), 
8.94 
-0.04 
(-0.13; 
0.06), 
0.436 
Treatme
nt:  
    AZT 
Refere
nce 
Refere
nce 
(N=20
9) 
Refere
nce 
Refere
nce 
(N=20
9) 
Refere
nce 
Refere
nce 
(N=21
0) 
Refere
nce  
Refere
nce 
(N=21
0) 
Refere
nce 
Refere
nce 
(N=21
0) 
   Triple 
therapy     
0.04 (-
0.11; 
0.19), 
0.605 
0.02 (-
0.13; 
0.16), 
0.797 
0.06 (-
0.08; 
0.20), 
0.422 
0.06 (-
0.08; 
0.20), 
0.406 
-0.12 (-
0.23; -
0.01), 
0.031 
-0.14 
(-
0.25; -
0.03), 
0.015 
4.27 (-
5.54; 
14.10), 
0.394 
3.66 (-
6.01; 
13.32)
, 
0.458 
0.01 (-
0.07; 
0.10), 
0.773 
0.01 (-
0.08; 
0.09), 
0.844 
Treatme
nt with 
unexpos
ed 
group:  
     HUU 
Refere
nce 
Refere
nce 
(N=97
7) 
Refere
nce 
Refere
nce 
(N=97
7) 
Refere
nce 
Refere
nce 
(N=98
6) 
Refere
nce  
Refere
nce 
(N=98
6) 
Refere
nce 
Refere
nce 
(N=98
6) 
     AZT -0.02 (-
0.16; 
0.12), 
0.759 
-0.01 
(-0.15; 
0.13), 
0.888 
0.02 (-
0.12; 
0.16), 
0.828 
-0.02 
(-0.16; 
0.12), 
0.751 
0.13 
(0.02; 
0.23), 
0.019 
0.08 (-
0.02; 
0.19), 
0.128 
-1.07 (-
10.35; 
8.21), 
0.821 
-0.61 
(-9.83; 
8.60), 
0.896 
0.01 (-
0.07; 
0.09), 
0.810 
-0.02 
(-0.10; 
0.06), 
0.557 
    Triple 
therapy     
0.02 (-
0.05; 
0.08), 
0.608 
0.02 (-
0.05; 
0.10), 
0.497 
0.07 
(0.01; 
0.13), 
0.033 
0.04 (-
0.03; 
0.11), 
0.288 
0.00 (-
0.04; 
0.05), 
0.888 
-0.06 
(-
0.11; -
0.01), 
0.028 
3.20 (-
0.91; 
7.31), 
0.127 
3.68 (-
0.86; 
0.821)
, 
0.112 
0.02 (-
0.01; 
0.06), 
0.219 
-0.02 
(-0.06; 
0.02), 
0.256 
*Multivariable mixed effect models adjusted for socio-economic status, race, sex, BMI for age, maternal 
smoke (cotinine results), LRTI 
#Undetectable: <40 copies/mL; detectable: 40-1000 copies/mL; virally unsuppressed: >1000 copies/mL 
Table 4 ART started before and during pregnancy (limited to children exposed to triple therapy 
currently recommended by WHO) with maternal CD4 at 6 weeks and 24 months 
 Log (FRC) LCI Log (tptef/te) Tidal Volume Log 
(Respiratory 
rate) 
 6 
weeks:  
Adjust
ed  
coeffic
ient  
(95% 
CI)*, p 
24 
month
s: 
Adjust
ed 
coeffic
ient  
(95% 
CI)**, 
p 
6 
weeks:  
Adjust
ed  
coeffic
ient  
(95% 
CI)*, p 
24 
month
s: 
Adjust
ed 
coeffic
ient  
(95% 
CI)**, 
p 
6 
weeks: 
Adjust
ed  
coeffic
ient  
(95% 
CI)*, p 
24 
month
s: 
Adjust
ed 
coeffic
ient  
(95% 
CI)**, 
p 
6 
weeks: 
Adjust
ed  
coeffic
ient  
(95% 
CI)*, p 
24 
month
s: 
Adjust
ed 
coeffic
ient  
(95% 
CI)**, 
p 
6 
weeks: 
Adjust
ed  
coeffic
ient  
(95% 
CI)*, p 
24 
month
s: 
Adjust
ed 
coeffic
ient  
(95% 
CI)**, 
p 
Antiretr
oviral 
therapy 
(ART) 
initiation
:  
   Before 
pregnan
cy 
Refere
nce  
(N=95
) 
Refere
nce  
(N=72
) 
Refere
nce  
(N=95
) 
Refere
nce  
(N=72
) 
Refere
nce 
 
(N=10
0) 
 
Refere
nce  
(N=76
) 
Refere
nce 
(N=10
0) 
 
Refere
nce  
(N=76
) 
Refere
nce 
(N=10
0) 
 
Refere
nce  
(N=76
) 
   During 
pregnan
cy     
-0.08 
(-0.18; 
0.01), 
0.073 
0.02 (-
0.07; 
0.11), 
0.655 
-0.12 
(-0.31; 
0.08), 
0.237 
-0.04 
(-0.31; 
0.22), 
0.743 
0.06 (-
0.08; 
0.20), 
0.390 
0.17 (-
0.01; 
0.35), 
0.059 
-2.70 
(-5.31; 
-0.10), 
0.042 
-5.67 
(-
12.82; 
1.48), 
0.118 
0.06 (-
0.05; 
0.17), 
0.275 
0.05 (-
0.01; 
0.12), 
0.120 
CD4 
(cells/m
m3):  
     > 500 
Refere
nce  
 
Refere
nce  
 
Refere
nce 
Refere
nce 
Refere
nce 
Refere
nce 
Refere
nce 
Refere
nce 
Refere
nce 
Refere
nce 
    350-
500 
0.03 (-
0.09; 
0.15), 
0.612 
-0.06 
(-0.19; 
0.06), 
0.302 
-0.23 
(-0.48; 
0.03), 
0.085 
-0.11 
(-0.46; 
0.23), 
0.513 
0.16 (-
0.03; 
0.35), 
0.091 
-0.04 
(-0.29; 
0.20), 
0.726 
-2.19 
(-5.61; 
1.24), 
0.208 
-11.70 
(-
21.46; 
-1.94), 
0.020 
0.03 (-
0.11; 
0.17), 
0.705 
0.00 (-
0.09; 
0.09), 
0.969 
     
<=350 
0.05 (-
0.06; 
0.15), 
0.367 
-0.03 
(-0.13; 
0.06), 
0.489 
-0.09 
(-0.31; 
0.12), 
0.390 
-0.10 
(-0.37; 
0.17), 
0.469 
0.14 (-
0.02; 
0.29), 
0.091 
0.03 (-
0.16; 
0.22), 
0.749 
-1.42 
(-4.30; 
1.46), 
0.329 
-11.08 
(-
18.58; 
-3.58), 
0.004 
0.02 (-
0.10; 
0.14), 
0.763 
0.06 (-
0.01; 
0.13), 
0.087 
 
*6-week multivariable models include ART initiation, CD4 categorical variables, socio-economic status, 
race, sex, BMI for age, maternal smoke (cotinine results); only HIV variables (ART and CD4 shown) 
**24-month multivariable models include ART initiation, CD4 categorical variables, socio-economic 
status, race, sex, BMI for age, infant smoke exposure (infant cotinine results), LRTI; only HIV variables 
(ART and CD4 shown) 
 
